This phase 3 trial is comparing how effective and safe bb2121 is when compared to standard of care regimens in relapsed and refractory multiple myeloma.
This trial is currently open and accepting patients.
Patients joining this trial will be randomized (like flipping of a coin) into two separate groups, Arm A and Arm B. The majority of patients will be added to Arm A, and receive bb2121. Arm B will receive one of five standard regimens. If you are placed into Arm B, and your myeloma worsens during treatment, you may be able to elect to receive bb2121.
Enrollment: 381 patients (estimated)View More
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.
There are additional locations that may be accepting patients that are not listed below. To find a participating center near you, please call SparkCures at (888) 828-2206.
View all clinical trial locations sorted by state.
Santa Monica, CA
New York, NY
Read the latest news and updates on this trial.
December 05, 2020
Patients with heavily pretreated multiple myeloma maintained durable responses with the chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel; bb2121) in updated findings presented from the phase 1 CRB-401 trial (NCT02658929).
June 01, 2018
Celgene Corporation and bluebird bio, Inc. today announced updated results from the ongoing CRB-401 phase I clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 43 patients with late-stage relapsed/refractory multiple myeloma.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message
SparkCures is working closely with Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors